PHARMESIS INTERNATIONAL LTD. (BFK) Fair Value & Analysis
Healthcare · SG · Market cap 13.2M SGD
Fair value as of: Aug 13, 2026
From 7 valuation models · updated 4 days ago
Share price −8.8% over the past month.
Below-average quality, and screening another 61% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.0562 SGD). The favourable scenario is already priced in.
- Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 0.0753 SGD – 0.6360 SGD · fair‑value band 0.0408 SGD – 0.0562 SGD · the 0.1250 SGD price screens above the 0.0485 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
PHARMESIS INTERNATIONAL LTD. (BFK) currently trades at 0.1250 SGD, while our model-based Fair Value estimate is 0.0485 SGD, implying the stock looks roughly 61.2% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, PHARMESIS INTERNATIONAL LTD. generated revenue of 43.8M SGD at a net margin of -9.8%. Revenue declined 62.2% year over year. It earns a return on equity of -7.4%. Net debt stands at 10.7M SGD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 0.0408 SGD (bear case) to 0.0562 SGD (bull case); at 0.1250 SGD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 74% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -61%, BFK screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Asset-Based (0.3500 SGD) versus DCF Models (0.2500 SGD). Highest evidence: Growth DCF (72).
Notify me when BFK reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China.
Full company description
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China. The company operates through three segments: Western drugs/TCH Procurement, TCM formulated drugs/IP Rental, and Distribution. It provides prescribed products and over-the-counter drugs. The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for rheumatoid arthritis and other rheumatic diseases treatment. It also provides Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat toxin; Shulinghou for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Fu Yang for the treatment skin pruritus and urticaria; and Xiong Dan Chuan Bei for the treatment of phlegm and cough. Further, the company distributes chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. The company provides western medicine products under the Kinna brand name; and TCM formulated products under the Longlife brand name. Pharmesis International Ltd. was founded in 1996 and is based in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PHARMESIS INTERNATIONAL LTD. reported revenue of 43.8M SGD in FY2025 versus 52.8M SGD in FY2021, a compound −4.6%/yr. Reported net income was −4.3M SGD in FY2025.
BFK screens 61% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare PHARMESIS INTERNATIONAL LTD. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PHARMESIS INTERNATIONAL LTD. (BFK) overvalued or undervalued?
What is the fair value of BFK?
What is the quality score of BFK?
What is the revenue of PHARMESIS INTERNATIONAL LTD. (BFK)?
What is the net profit margin of BFK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PHARMESIS INTERNATIONAL LTD. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.